CN110205383A - A kind of application of LncRNA marker in lung cancer immune function is detected or assessed - Google Patents

A kind of application of LncRNA marker in lung cancer immune function is detected or assessed Download PDF

Info

Publication number
CN110205383A
CN110205383A CN201910409727.8A CN201910409727A CN110205383A CN 110205383 A CN110205383 A CN 110205383A CN 201910409727 A CN201910409727 A CN 201910409727A CN 110205383 A CN110205383 A CN 110205383A
Authority
CN
China
Prior art keywords
lncrna
lung cancer
runxor
application
immune function
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201910409727.8A
Other languages
Chinese (zh)
Inventor
李敏
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jiangsu University
Original Assignee
Jiangsu University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu University filed Critical Jiangsu University
Priority to CN201910409727.8A priority Critical patent/CN110205383A/en
Publication of CN110205383A publication Critical patent/CN110205383A/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The present invention relates to molecular biology application fields, and in particular to a kind of application of LncRNA marker in lung cancer immune function is detected or assessed.Invention has found that LncRNA RUNXOR has obvious differential expression in blood of patients with lung cancer for the first time, compared with normal population control group, patients with lung cancer test group has highly expressed LncRNA molecular marked compound RUNXOR, and the expression of postoperative LncRNA RUNXOR is obviously lowered；The differentiation of the expression regulation MDSCs of RUNX1 and immune suppression function.Based on this discovery, LncRNA RUNXOR can be used as the molecular marker for adjusting lung cancer immune function or target spot is applied to lung cancer clinical diagnosis or targeted therapy, it can be applied to lung cancer immune function by detection LncRNA RUNXOR provided by the present invention to detect/assess in product, be conducive to further elucidate lung cancer occurrence and development mechanism, there is important directive significance to the treatment of lung cancer.

Description

A kind of application of LncRNA marker in lung cancer immune function is detected or assessed
Technical field
The present invention relates to molecular biology application fields, and in particular to a kind of LncRNA marker is examined in lung cancer immune function Application in surveying or assessing.
Background technique
In China, the morbidity and mortality of lung cancer occupy malignant tumour first place.At present patients with lung cancer early diagnosis, Monitor of Immune Function and the biomarker of prognosis are very deficient, and 5 years survival rates of traditional treatment Patients with Advanced Lung Cancer are lower than 5%, the effective biomarker for exploring lung cancer is significant for the therapeutic effect for improving patients with lung cancer.
Existing research discovery LncRNA RUNXOR can be in the expression of epigenetic level modulation RUNX1.In acute marrow In cell leukemia cell, lncRNA RUNXOR is bonded directly in the promoter and enhancer of RUNX1 and is joined by its 3 ' end With chromatin remodeling.In addition to this, LncRNA RUNXOR can also directly recruit RUNX1 albumen and be bound to RUNX1 gene and open Sub-area and then the expression for promoting RUNX1.
Immunosuppressive condition is integrally presented in patients with lung cancer body, a group has the marrow source property of immune suppression function in peripheral blood It is significantly raised to inhibit cell (MDSCs) ratio, and Th1 the and CTL cell proportion for participating in Antitumor immunity response is substantially reduced. MDSCs is made of as a group heterogeneity cell immature bone marrow cell.In healthy human body, these immature marrow Cell breaks up rapidly as mature granulocyte, macrophage, DC cell.Under some pathological conditions, such as tumour, inflammation, These immature Differentiation of Bone Marrow Cells are blocked so as to cause MDSCs massive amplification.MDSCs has immune suppression function, energy Enough negative regulation immune responses, effectively inhibit the immune response of T cell, promote the growth of tumour.In blood of cancer patients Negative correlativing relation is often presented in the ratio and Th1 and CTL cell proportion of MDSCs.In general, tumor patient immune function is got over Weak, the quantity of internal MDSCs is more, and the quantity of Th1 and CTL cell is fewer.Mankind's MDSCs phenotype is Lin-CD14-CD11b+ CD33+CD34+HLA-DR-/lo, and had differences in the expression of CD15 and other labels.MDSCs mainly passes through generation and exempts from Epidemic disease inhibits molecule such as arginase (Arg1), iNOS (iNOS) and active oxygen ROS) it plays to T cell Jie The inhibiting effect for the antineoplastic immune led.But the application about LncRNA RUNXOR in lung cancer Analysis of Immunological Function disease It yet there are no report.
Summary of the invention
In order to make up some shortcomings of the prior art, the present invention provides the new application of LncRNA RUNXOR a kind of, for solving Some problems certainly in the prior art.The LncRNA RUNXOR is in Gene ID:NM_001001890.2, length 216 Kb shares exon and introne with RUNX1 gene.
The present invention also provides a kind of product of lung cancer Analysis of Immunological Function, the product can analyze LncRNA The expression of RUNXOR.Wherein, in peripheral blood from patients with lung cancer the expression of LncRNA RUNXOR and patients with lung cancer immunocompetence It is positively correlated.Further, the product includes kit, probe, chip or preparation.
Further, the kit includes the Specific PCR primers or probe of above-mentioned LncRNA RUNXOR marker.Institute Stating kit further includes dNTP, random primer, reducing agent, RNase inhibitor, reverse transcriptase, MgCl2With in PCR buffer etc. One or more combinations, in addition, the kit can also contain standard items and/or reference substance.Further, mentioned reagent Box includes also preferably some other auxiliary reagent, and the auxiliary reagent is conventional use of in quantitative pcr amplification kit Some reagents, the characteristic of these reagents and their preparation method are well-known to those skilled in the art；The examination Agent such as (but not limited to): negative controls, positive reference substance；It can also include quantitative fluorescent PCR reaction plate, PCR reaction plate Sealed membrane etc..Further, the chip includes: solid phase carrier, and the oligonucleotides being orderly fixed on the solid phase carrier Probe, the oligonucleotide probe specifically correspond to some or all of above-mentioned LncRNA marker sequence.Wherein, solid phase Carrier includes sheet glass, silicon wafer, polypropylene screen, nitrocellulose filter, nylon membrane or polystyrene film.
The present invention provides a kind of the said goods to treat the application in the tool for adjusting lung cancer immune function in preparation.This hair Tool in bright can be used for detecting the expression of multiple genes including LncRNA RUNXOR.
Detection in the present invention includes but is not limited to sequencing technologies, nucleic acid hybridization technique, nucleic acid amplification technologies or immune survey Fixed, nucleic acid amplification technologies include but is not limited to the expansion of polymerase chain reaction, reverse transcriptase polymerase chain reaction, transcriptive intermediate Increasing, ligase chain reaction, strand displacement amplification or the amplification based on nucleic acid sequence.
The present invention also provides above-mentioned LncRNA RUNXOR to treat answering in the drug for adjusting lung cancer immune function in preparation With.
Compared with prior art, the beneficial effects of the present invention are:
Present invention firstly discovers that LncRNA RUNXOR has obvious differential expression in blood of patients with lung cancer, and just Ordinary person's group's control group is compared, and patients with lung cancer test group has highly expressed LncRNA molecular marked compound RUNXOR, postoperative LncRNA The expression of RUNXOR is obviously lowered；Expression and patient of the LncRNA RUNXOR in peripheral blood from patients with lung cancer The expression of MDSC ratio and Arg1 are positively correlated with the ratio of Th1, CTL cell in obvious, RUNX1 in obvious negative correlation Expression regulation MDSCs differentiation and immune suppression function.Based on this discovery, LncRNA RUNXOR can be used as adjusting lung cancer The molecular marker or target spot of immune function are applied to lung cancer clinical diagnosis or targeted therapy, provided by the present invention by detecting LncRNA RUNXOR can be applied to lung cancer immune function and detect/assess in product, is conducive to further elucidate lung cancer and send out It opens up mechanism, there is important directive significance to the treatment of lung cancer.
Detailed description of the invention
Fig. 1 is experimental group, LncRNA RUNXOR in different type peripheral blood from patients with lung cancer in control group and experimental group Expression figure；
Fig. 2 is the expression comparison diagram of lncRNA RUNXOR in peripheral blood from patients with lung cancer before operative treatment and after treatment；
Fig. 3 be experimental group, in control group and experimental group in different type peripheral blood from patients with lung cancer sample MDSCs comparison diagram；
Fig. 4 be experimental group, in control group peripheral blood sample Th1/CTL comparative analysis figure；
Fig. 5 is the ratio comparison diagram of MDSC and Th1/CTL in experimental group and control group；
Fig. 6 is the correlation analysis figure of experimental group LncRNA RUNXOR expression and MDSCs ratio and Arg1 level；
Fig. 7 is experimental group LncRNA RUNXOR expression and Th1/CTL ratio correlation analysis figure specific embodiment
With reference to the accompanying drawing, the present invention is further illustrated, these embodiments are merely to illustrate the present invention rather than limit this hair Bright range；Test method without specific conditions in embodiment, according to normal conditions, kit used in embodiment The amount of reagent is merely exemplary, and those skilled in the art can be adjusted accordingly according to the actual situation；The reagent and biology Material commercially obtains unless otherwise specified.
It would be recognized by those skilled in the art that practicability of the invention is not limited to marker gene of the invention The gene expression of any specific variants is quantified.In specific embodiments of the present invention, gene level is raised and lowered Reduction usually compared with the control.Technical staff can select maximally related control.This is also generally dependent on institute's study of disease Property, obtainable sample etc..Suitable control includes but is not limited to similar sample, control from non-lung cancer patient The average level or one group of clinical data in relation to gene product average level in sampling tissue of group.From it is above-mentioned can be clearly Out, control can come from identical subject or from one or more different subject or from clinical data.It is optional Ground, to impinge upon such as gender, the age on match.
Embodiment 1:
(1) collection and processing of sample
Collect the peripheral blood sample (adenocarcinoma of lung 53, squamous cell carcinoma 24, Small Cell Lung Cancer 23) of 100 patients with lung cancer It is control group for experimental group, 100 healthy peripheral blood samples.In addition, respectively collect 40 operative treatments before and treatment after lung Cancer patient peripheral's blood sample, these samples meet following standard: (1) patient is to be diagnosed as lung cancer for the first time and undergo surgery for the first time Treatment；(2) postoperative sample is to acquire after 7 days after performing the operation.Above-mentioned all equal informed consents of sample supplier, the acquirement of sample are logical Cross the agreement of the committee, organizational ethics.
By 2 ml K218 DEG C of peripheric venous blood of EDTA anticoagulant tube acquisition, 2000 rpm/min are centrifuged 5min, separated plasma And haemocyte, haemocyte are resuspended using 6 ~ 8 ml ACK, stand 500g centrifugation 5min after 10 min at room temperature；It discards supernatant, carefully Born of the same parents' precipitating is washed twice with 10 ml PBS buffer solution, and each 500g is centrifuged 5min, is discarded supernatant, cell precipitation bullet is even, spare.
(2) qRT-PCR detects the expression of LncRNA RUNXOR molecule
Treated, and 1ml Trizol(Invitrogen is added in haemocyte), it is mixed by inversion for several times, extracted total RNA, reverse transcription closes At cDNA(Toyobo ReverTra Aca qPCR RT Kit kit (Code No.:FSQ-101)).Using cDNA as mould Plate is added LncRNA RUNXOR primer and carries out PCR.Using being detected on Bio Rad (CFX96) fluorescence quantitative PCR instrument. Target gene relative expression quantity is calculated with β-actin.
The forward primer sequence of the LncRNA RUNXOR is as shown in SEQ ID NO.1, it may be assumed that 5 '- CCTGTTCACGGTCCAAACTGG-3' ；The reverse primer sequences of LncRNA RUNXOR are as shown in SEQ ID NO.2, it may be assumed that 5 '- CGGCAAGATCACAGTCCCTAGC-3' ；The forward primer sequence of the β-actin is as shown in SEQ ID NO.3, it may be assumed that 5 '- The reverse primer sequences of CACGAAACTACCTTCAACTCC-3 ', β-actin are as shown in SEQ ID NO.4, it may be assumed that 5 '- CATACTCCTGCTTGCTGATC-3’。
Fig. 1 is experimental group, LncRNA RUNXOR in different type peripheral blood from patients with lung cancer in control group and experimental group Expression figure；Wherein, figure A be experimental group, control group peripheral blood in LncRNA RUNXOR expression comparison diagram, scheme B It is the expression comparison diagram of lncRNA RUNXOR in different type peripheral blood from patients with lung cancer in experimental group.As seen from Figure 1, phase Compared with control group, the expression of lncRNA RUNXOR is significantly increased in experimental group, LncRNA in different type peripheral blood from patients with lung cancer The expression of RUNXOR is significantly raised.Fig. 2 is lncRNA in peripheral blood from patients with lung cancer before operative treatment and after treatment The expression comparison diagram of RUNXOR；From Figure 2 it can be seen that being treated surgically in peripheral blood from patients with lung cancer after a week for the first time The expression of LncRNA RUNXOR is substantially reduced.
The detection of Arg1 expression in embodiment 2:MDSCs, Th1 cell, CTL cell proportion and MDSCs
(1) peripheral blood phenotype is CD33 in experimental group and control group+CD11b+CD14-HLA-DR-MDSCs ratio.
According to 1 × 106Cell/100 μ L are added PBS and cell precipitation are resuspended, and PE-anti-human-CD14, PE/ is added CY5-anti-human-CD11b, APC-anti-human-HLA-DR and FITC-anti-human-CD33 antibody are corresponding Each 0.25 μ g of Isotype antibody.4 DEG C are protected from light mixing 30min, and cell is resuspended in 200 μ L PBS after being washed with PBS, uses fluidic cell Instrument (FCM) detects the ratio of MDSCs in peripheral blood.
Fig. 3 be experimental group, in control group and experimental group in different type peripheral blood from patients with lung cancer sample MDSCs comparison Figure；As shown in figure 3, the expression quantity of MDSCs is significantly raised compared in control group in experimental group, and different Lung Cancer Types peripheral blood in patients The ratio of middle MDSCs is significantly raised.
(2) in experimental group and control group peripheral blood Th1 and CTL cell detection
Separate PBMCs from patients with lung cancer/health peripheral blood sample using Ficoll density-gradient centrifugation method, then according to 1.0×106/ hole is added in 24 orifice plates, and 50ng/mL PMA, 1 μ g/mL ionomycin is added, adds 1 μ g/ml BFA 37 °C, 5% CO2Under the conditions of cultivate 4h.Cell is collected, fluorescent antibody staining is carried out.PE/CY5-anti-human- is used first After CD3 and FITC-anti-human-CD8 mAbs dyes 30min, rupture of membranes continues to use PE-anti-human-IFN- γ MAb dyes 45min.It is detected using flow cytometer (FCM).Fig. 4 is experimental group, Th1/ in control group peripheral blood sample The comparative analysis figure of CTL；As shown in figure 4, the ratio of experimental group Th1/CTL is significantly reduced compared with control group.
(3) in experimental group and control group in peripheral blood MDSCs Arg1 expression detection
QRT-PCR method of the qRT-PCR detection method as described in (2) in embodiment 1 carries out.Wherein, 18S forward primer sequence is such as Shown in SEQ ID NO.5, it may be assumed that 5 '-CGGACAGGATTGACAGATTG-3 ', 18S reverse primer sequences such as SEQ ID NO.6 institute Show, it may be assumed that 5 '-GCCAGAGTCTCGTTCGTTATC-3 '；Wherein, the forward primer sequence of Arg1 is as shown in SEQ ID NO.7, That is: 5 '-CCTTTGCTGACATCCCTAAT-3 ', Arg1 reverse primer sequences are as shown in SEQ ID NO.8, it may be assumed that 5 '- GATTCTTCCGTTCTTCTTGACT-3’。
Fig. 5 is the ratio comparison diagram of MDSC and Th1/CTL in experimental group and control group；As shown in figure 5, the ratio of MDSCs Ratio with Th1/CTL is in obvious negatively correlated.
Embodiment 3: the expression of LncRNA RUNXOR and MDSCs, Th1 cell in peripheral blood, CTL cell proportion with And in MDSCs Arg1 expression correlation analysis
Statistical procedures are carried out using 5.0 software of GraphPad Prism, data are in normal distribution, using Student ' s t- test.Correlation analysis is analyzed using Spearman's correlation coefficient.P < 0.05 is that difference has statistics Learn meaning.Fig. 6 is the correlation analysis figure of experimental group LncRNA RUNXOR expression and MDSCs ratio and Arg1 level；Figure 7 be experimental group LncRNA RUNXOR expression and Th1/CTL ratio correlation analysis figure；As shown in Figure 6,7, pass through correlation Property analysis, find peripheral blood from patients with lung cancer in LncRNA RUNXOR expression and MDSCs cell proportion and MDSCs master It wants effector molecule Arg1 expression to be positively correlated in apparent, is presented with the ratio of Th1/CTL apparent negatively correlated.
Although above the present invention is described in detail with a general description of the specific embodiments, On the basis of the present invention, it can be made some modifications or improvements, this will be apparent to those skilled in the art.Cause This, these modifications or improvements, fall within the scope of the claimed invention without departing from theon the basis of the spirit of the present invention.
Sequence table
<110>Jiangsu University
<120>application of a kind of LncRNA marker in lung cancer immune function is detected or assessed
<160> 8
<170> SIPOSequenceListing 1.0
<210> 1
<211> 21
<212> DNA
<213>artificial sequence (Artificial Sequence)
<400> 1
cctgttcacg gtccaaactg g 21
<210> 2
<211> 22
<212> DNA
<213>artificial sequence (Artificial Sequence)
<400> 2
cggcaagatc acagtcccta gc 22
<210> 3
<211> 21
<212> DNA
<213>artificial sequence (Artificial Sequence)
<400> 3
cacgaaacta ccttcaactc c 21
<210> 4
<211> 20
<212> DNA
<213>artificial sequence (Artificial Sequence)
<400> 4
catactcctg cttgctgatc 20
<210> 5
<211> 20
<212> DNA
<213>artificial sequence (Artificial Sequence)
<400> 5
cggacaggat tgacagattg 20
<210> 6
<211> 21
<212> DNA
<213>artificial sequence (Artificial Sequence)
<400> 6
gccagagtct cgttcgttat c 21
<210> 7
<211> 20
<212> DNA
<213>artificial sequence (Artificial Sequence)
<400> 7
cctttgctga catccctaat 20
<210> 8
<211> 22
<212> DNA
<213>artificial sequence (Artificial Sequence)
<400> 8
gattcttccg ttcttcttga ct 22
Sequence table
<110>Jiangsu University
<120>application of a kind of LncRNA marker in lung cancer immune function is detected or assessed
<160> 8
<170> SIPOSequenceListing 1.0
<210> 1
<211> 21
<212> DNA
<213>artificial sequence (Artificial Sequence)
<400> 1
cctgttcacg gtccaaactg g 21
<210> 2
<211> 22
<212> DNA
<213>artificial sequence (Artificial Sequence)
<400> 2
cggcaagatc acagtcccta gc 22
<210> 3
<211> 21
<212> DNA
<213>artificial sequence (Artificial Sequence)
<400> 3
cacgaaacta ccttcaactc c 21
<210> 4
<211> 20
<212> DNA
<213>artificial sequence (Artificial Sequence)
<400> 4
catactcctg cttgctgatc 20
<210> 5
<211> 20
<212> DNA
<213>artificial sequence (Artificial Sequence)
<400> 5
cggacaggat tgacagattg 20
<210> 6
<211> 21
<212> DNA
<213>artificial sequence (Artificial Sequence)
<400> 6
gccagagtct cgttcgttat c 21
<210> 7
<211> 20
<212> DNA
<213>artificial sequence (Artificial Sequence)
<400> 7
cctttgctga catccctaat 20
<210> 8
<211> 22
<212> DNA
<213>artificial sequence (Artificial Sequence)
<400> 8
gattcttccg ttcttcttga ct 22

Claims (7)

  1. The application of 1.LncRNA RUNXOR marker, which is characterized in that the application is LncRNA RUNXOR in preparation lung cancer Immune function detects/assesses the application in information products.
  2. 2. application according to claim 1, which is characterized in that the product includes analysis LncRNA RUNXOR expression Kit, probe, chip or preparation.
  3. 3. application according to claim 2, which is characterized in that the kit includes LncRNA RUNXOR marker Specific PCR primers or probe.
  4. 4. application according to claim 3, which is characterized in that the kit further includes dNTP, random primer, reduction Agent, RNase inhibitor, reverse transcriptase, MgCl2With one of PCR buffer etc. or a variety of combinations.
  5. 5. application according to claim 2, which is characterized in that the chip includes: solid phase carrier and is orderly fixed on Oligonucleotide probe on the solid phase carrier, the oligonucleotide probe specifically correspond to the portion of LncRNA RUNXOR Point or full sequence.
  6. 6. application according to claim 1, which is characterized in that the application is that LncRNA RUNXOR is adjusted in preparation treatment Save the application in the tool of lung cancer immune function.
  7. 7. application according to claim 1, which is characterized in that the application is that LncRNA RUNXOR is adjusted in preparation treatment Save the application in the drug of lung cancer immune function.
CN201910409727.8A 2019-05-16 2019-05-16 A kind of application of LncRNA marker in lung cancer immune function is detected or assessed Pending CN110205383A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201910409727.8A CN110205383A (en) 2019-05-16 2019-05-16 A kind of application of LncRNA marker in lung cancer immune function is detected or assessed

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201910409727.8A CN110205383A (en) 2019-05-16 2019-05-16 A kind of application of LncRNA marker in lung cancer immune function is detected or assessed

Publications (1)

Publication Number Publication Date
CN110205383A true CN110205383A (en) 2019-09-06

Family

ID=67787469

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201910409727.8A Pending CN110205383A (en) 2019-05-16 2019-05-16 A kind of application of LncRNA marker in lung cancer immune function is detected or assessed

Country Status (1)

Country Link
CN (1) CN110205383A (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112195224A (en) * 2020-10-23 2021-01-08 漯河医学高等专科学校 Application of gene combined detection reagent in immunotherapy of lung cancer patients

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
XINYU TIAN 等: "Long non-coding RNA RUNXOR accelerates MDSC-mediated immunosuppression in lung cancer", 《BMC CANCER》 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112195224A (en) * 2020-10-23 2021-01-08 漯河医学高等专科学校 Application of gene combined detection reagent in immunotherapy of lung cancer patients

Similar Documents

Publication Publication Date Title
US10894984B2 (en) Method for identifying the quantitative cellular composition in a biological sample
Agnelli et al. Identification of a 3-gene model as a powerful diagnostic tool for the recognition of ALK-negative anaplastic large-cell lymphoma
JP2018520672A (en) How to diagnose bladder cancer
MX2008011839A (en) Propagation of primary cells.
CN107636172A (en) For diagnosing, predicting or monitoring the instrument of pneumocystis pneumonia
CN110093413A (en) Detect the primer sets and kit of beta Thalassemia
CN109825586A (en) DNA methylation qPCR kit and application method for lung cancer detection
Gladkikh et al. Cyclin D1 expression in B-cell lymphomas
CN109112216A (en) The kit and method of triple qPCR detection DNA methylations
JP2011526148A (en) DNA methylation analysis of regulatory T cells by DNA methylation analysis of TSDR region of gene foxP3
CA3026809A1 (en) Compositions and methods for diagnosing lung cancers using gene expression profiles
CN105567861B (en) Purposes of the IFI27 as diagnosis of coronary heart disease marker
CA3146980A1 (en) Genetic marker combination and use thereof
CN107447042A (en) Molecular marker and its application for diagnostic activities tuberculosis disease
CN108866187B (en) Long-chain non-coding RNA marker related to lung cancer auxiliary diagnosis and application thereof
CN109913482A (en) PIK3CA-I874R mutated gene and its application in Computer-aided Diagnosis of Breast Cancer
CN110205383A (en) A kind of application of LncRNA marker in lung cancer immune function is detected or assessed
WO2010032797A1 (en) Breast cancer metastasis determination method and blood serum evaluation method
Fujieda et al. Granulocytic sarcoma of mesentery in acute myeloid leukemia with CBFB/MYH11 fusion gene but not inv (16) chromosome: case report and review of literature
CN112534068A (en) Method for early diagnosis and post-treatment monitoring of breast cancer using fluid biopsy of multiple oncogene biomarkers
CN114134164A (en) RARA-WIPF2 fusion gene and application and detection kit thereof
Sakamoto et al. WT1 mRNA level in peripheral blood is a sensitive biomarker for monitoring minimal residual disease in acute myeloid leukemia
Westwood et al. Polycythemia vera: analysis of DNA from blood granulocytes using comparative genomic hybridization
JP6017448B2 (en) Diagnosis method of blood diseases
CN107151699A (en) Detect the kit and method of NUP214 ABL1 gene relative expression quantities

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination